U.S. Markets open in 5 hrs 38 mins

Kiniksa Pharmaceuticals, Ltd. (KNSA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.21-0.55 (-2.93%)
At close: 4:00PM EDT

Kiniksa Pharmaceuticals, Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
808 189 6257
http://www.kiniksa.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees135

Key Executives

NameTitlePayExercisedYear Born
Mr. Sanj K. PatelCEO & Chairman1.25MN/A1970
Dr. John F. PaoliniSr. VP & Chief Medical Officer593.88kN/A1965
Mr. Qasim Rizvi M.B.A.Sr. VP of Operations & Chief Commercial Officer920.3kN/A1970
Mr. Michael R. MegnaPrincipal Financial Officer & Chief Accounting OfficerN/AN/A1971
Mr. Thomas W. BeethamExec. VP of Corp. Devel. & Operations, Chief Legal Officer and Sec.N/AN/A1970
Mr. Dave NicholsSr. VP of Technical OperationsN/AN/AN/A
Mark Ragosa C.F.A.VP of Investor RelationsN/AN/AN/A
Ms. Melissa MannoVP of HRN/AN/AN/A
Mr. Rasmus Holm-JorgensenSr. VP, Chief Strategy & Portfolio OfficerN/AN/AN/A
Mr. Carsten BoessExec. VP of Corp. AffairsN/AN/A1967
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Corporate Governance

Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of October 6, 2020 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.